

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 2/13/06

Signature: Jeffrey S. Sharp

Jeffrey S. Sharp

Docket No.: 30985/41486
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Francois Spertini et al.

Application No.: 10/799,514

Confirmation No.: 8487

Filed: March 12, 2004

Art Unit: 1644

For: ALLERGEN PEPTIDE FRAGMENTS AND
USE THEREOF

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of the cited U.S. patents and U.S. patent applications as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other

material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30985/41486. A duplicate copy of this paper is enclosed.

Dated:

Respectfully submitted,

By


Jeffrey S. Sharp

Registration No.: 31,879

MARSHALL, GERSTEIN & BORUN LLP


233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/799,514-Conf. #8487
				Filing Date	March 12, 2004
				First Named Inventor	Francois Spertini
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	30985/41486

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-5,767,075	06-16-1998	Avruch <i>et al.</i>	
	A2*	US-6,042,831	03-28-2000	Beretta	
	A3*	US-20020193295-A1	12-19-2002	Calenoff <i>et al.</i>	
	A4*	US-20030211510-A1	11-13-2003	Henderson <i>et al.</i>	
	A5*	US-6,649,166	11-18-2003	Maillere <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-00/44887	08-03-2000	Commissariat Energie Atomique <i>et al.</i>		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the iFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Akdis <i>et al.</i> , "Epitope-Specific T Cell Tolerance to Phospholipase A(2) in Bee Venom Immunotherapy and Recovery by IL-2 and IL-15 in Vitro," <i>J. Clin. Invest.</i> , 98:1676-83, 1996.	
	C2	Akdis <i>et al.</i> , "Role of Interleukin 10 in Specific Immunotherapy," <i>J. Clin. Invest.</i> , 102:98-106, 1998.	
	C3	Bauer <i>et al.</i> , "Modulation of the Allergic Immune Response in BALB/c Mice by Subcutaneous Injection of High Doses of the Dominant T Cell Epitope from the Major Birch Pollen Allergen Bet v 1," <i>Clin. Exp. Immunol.</i> , 107:536-41, 1997.	
	C4	Briner <i>et al.</i> , "Peripheral T-Cell Tolerance Induced in Naive and Primed Mice by Subcutaneous Injection of Peptides from the Major Cat Allergen Fel d 1," <i>Proc. Natl. Acad. Sci. USA</i> , 90:7608-12, 1993.	
	C5	Casari <i>et al.</i> , "A Method to Predict Functional Residues in Proteins," <i>Structural Biology</i> , 2(2):171-178, February 1995.	
	C6	De Waal <i>et al.</i> , "Direct Effects of IL-10 on Subsets of Human CD4+ T Cell Clones and Resting T Cells. Specific Inhibition of IL-2 Production and Proliferation," <i>J. Immunol.</i> , 150:4754-65, 1993.	
	C7	Ferreira <i>et al.</i> , "Dissection of Immunoglobulin E and T Lymphocyte Reactivity of Isoforms of the Major Birch Pollen Allergen Bet v 1: Potential Use of Hypoallergenic Isoforms for Immunotherapy," <i>J. Exp. Med.</i> , 183:559-609, February 1996.	
	C8	Ferreira <i>et al.</i> , "Modulation of IgE Reactivity of Allergens by Site-Directed Mutagenesis: Potential Use of Hypoallergenic Variants for Immunotherapy," <i>The FASEB Journal</i> , 12:231-242, February 1998.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/799,514-Conf. #8487
				Filing Date	March 12, 2004
				First Named Inventor	Francois Spertini
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	30985/41486

C9	Groux <i>et al.</i> , "Interleukin-10 Induces a Long-Term Antigen-Specific Anergic State in Human CD4+ T Cells," <i>J. Exp. Med.</i> , 184:19-29, 1996.	
C10	Hansen <i>et al.</i> , "Allergen-Specific Th1 Cells Fail to Counterbalance Th2 Cell-Induced Airway Hyperreactivity but Cause Severe Airway Inflammation," <i>J. Clin. Invest.</i> 103:175-83, 1999.	
C11	Haselden, <i>et al.</i> , "Immunoglobulin E-Independent Major Histocompatibility Complex-Restricted T Cell Peptide Epitope-Induced Late Asthmatic Reactions," <i>J. Exp. Med.</i> , 189:1885-94, 1999.	
C12	Hoyne <i>et al.</i> , "Regulation of House Dust Mite Responses by Intranasally Administered Peptide: Transient Activation of CD4+ T Cells Precedes the Development of Tolerance in Vivo," <i>Int. Immunol.</i> , 8:335-42, 1996.	
C13	International Preliminary Report on Patentability from PCT/IB04/01300 dated October 10, 2004.	
C14	International Search Report from PCT/IB04/01300 dated October 4, 2004.	
C15	Jutel, <i>et al.</i> , "Selective Restimulation of Antigen or Allergen Preactivated T Cells Using OKT3 F(ab)(2) Results in the Secretion of TH-1 or TH-2-Like Cytokine Patterns," <i>Clin. Experiment. Allergy</i> , 25:1108-17, 1995.	
C16	Kettner, <i>et al.</i> , "IgE and T-Cell Responses to High-Molecular Weight Allergens from Bee Venom," <i>Clin. Experiment. Allergy</i> , 29:394-401, 1999.	
C17	King <i>et al.</i> , "Antibody Responses to Bee Melittin (Api m 4) and Hornet Antigen 5 (Dol m 5) in Mice Treated with the Dominant T-Cell Epitope Peptides," <i>J. Allerg. Clin. Immunol.</i> , 101:397-403, 1998.	
C18	Larche, "Allergen-Derived T Cell Peptides in Immunotherapy," <i>Revue Francaise D'Allergologie et D'Immunologie Clinique 2003 France</i> , 43(1):59-63, 2003.	
C19	Larche, "Peptide-Based Therapeutic Vaccines for Allergic and Autoimmune Diseases," <i>Nat. Med.</i> , 11(4 Suppl):S69-76, 2005.	
C20	Laver <i>et al.</i> , "Epitopes on Protein Antigens: Misconceptions and Realities," <i>Cell</i> , 61:553-556, May 1990.	
C21	Lesourd <i>et al.</i> , "Hymenoptera Venom Immunotherapy: Relationships with Specific Antibody Responses," <i>J. Allergy Clin. Immunol.</i> , 83:563-71, 1989.	
C22	Malvey <i>et al.</i> , "Peripheral Immune Tolerance Blocks Clonal Expansion but Fails to Prevent the Differentiation of Th1 Cells," <i>J. Immunol.</i> , 161:2168-77, 1998.	
C23	Mueller, "Diagnosis and Treatment of Insect Sensitivity," <i>J. Asthma Res.</i> , 3:331-3, 1966.	
C24	Müller <i>et al.</i> , "Immunotherapy with Honeybee Venom and Yellow Jacket Venom is Different Regarding Efficacy and Safety," <i>J. Allergy Clin. Immunol.</i> , 89:529-35, 1992.	
C25	Müller, <i>Insect Sting Allergy: Clinical Picture, Diagnosis and Treatment</i> , Stuttgart, New York:1990.	
C26	Müller <i>et al.</i> , "Position Paper: Immunotherapy with Hymenoptera Venoms," <i>Allergy</i> , 48(Suppl. 14):37-46, 1993.	
C27	Müller <i>et al.</i> , "Predictive Value of Venom-Specific IgE, IgG and IgG Subclass Antibodies in Patients on Immunotherapy with Honey Bee Venom," <i>Allergy</i> , 44:412-8, 1989.	
C28	Müller <i>et al.</i> , "Type I Skin Reactivity to Native and Recombinant Phospholipase A(2) from Honeybee Venom is Similar," <i>J. Allerg. Clin. Immunol.</i> , 96:395-402, 1995.	
C29	Norman <i>et al.</i> , "Treatment of Cat Allergy with T-Cell Reactive Peptides," <i>Am. J. Respir. Crit. Care Med.</i> , 154:1623-8, 1996.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/799,514-Conf. #8487
				Filing Date	March 12, 2004
				First Named Inventor	Francois Spertini
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	30985/41486

C30	Oldfield, <i>et al.</i> , "Allergen-Derived T Cell Peptide-Induced Late Asthmatic Reactions Precede the Induction of Antigen-Specific Hyporesponsiveness in Atopic Allergic Asthmatic Subjects," <i>J. Immunol.</i> , 167:1734-9, 2001.	
C31	Ollert <i>et al.</i> , "Prognostic Value of Immunoblotting in Patients on Immunotherapy with Hymenoptera Venom," <i>J. Allergy Clin. Immunol.</i> , 105:S59, Abstract 178, 2000.	
C32	Pape, <i>et al.</i> , "Direct Evidence that Functionally Impaired CD4+ T Cells Persist in Vivo Following Induction of Peripheral Tolerance," <i>J. Immunol.</i> , 160:4719-29, 1998.	
C33	Punnonen, "Molecular Breeding of Allergy Vaccines and Antiallergic Cytokines," <i>International Archives of Allergy and Immunology</i> , 121(3):173-182, 2000.	
C34	Roggero <i>et al.</i> , "A Simple and Rapid Procedure for the Purification of Synthetic Polypeptides by a Combination of Affinity Chromatography and Methionine Chemistry," <i>FEBS Letters</i> , 408:285-8, 1997.	
C35	Rueff <i>et al.</i> , "Ultrarush Immunotherapy in Patients with Hymenoptera Venom Allergy," <i>J. Allergy Clin. Immunol.</i> , 107:928-9, 2001.	
C36	Schneider <i>et al.</i> , "Human Monoclonal or Polyclonal Antibodies Recognize Predominantly Discontinuous Epitopes on Bee Venom Phospholipase A ₂ ," <i>J. Allergy Clin. Immunol.</i> , 94(1):61-70, July 1994.	
C37	Smith <i>et al.</i> , "Recombinant Allergens for Immunotherapy: A Der p2 Variant with Reduced IgE Reactivity Retains T-Cell Epitopes," <i>J. Allergy Clin. Immunol.</i> , 101(3):423-425, 1998.	
C38	Takai <i>et al.</i> , "Engineering of the Major House Dust Mite Allergen Der f 2 for Allergen-Specific Immunotherapy," <i>Nature Biotechnology</i> , 15:754-758, August 1997.	
C39	Tsitoura <i>et al.</i> , "Intranasal Exposure to Protein Antigen Induces Immunological Tolerance Mediated by Functionally Disabled CD4+ T Cells," <i>J. Immunol.</i> , 163:2592-600, 1999.	
C40	Urbanek <i>et al.</i> , "Sub-Class of IgG Anti-Bee Venom Antibody Produced During Bee Venom Immunotherapy and Its Relationship to Long-Term Protection from Bee Stings and Following Termination of Venom Immunotherapy," <i>Clin. Allergy</i> , 16:317-22, 1986.	
C41	Van Neerven <i>et al.</i> , "Characterization of Cat Dander-Specific T Lymphocytes from Atopic Patients," <i>J. Immunol.</i> , 152:4203-10, 1994.	
C42	Van Neerven <i>et al.</i> , "T Cell Epitopes of House Dust Mite Major Allergen Der p II," <i>J. Immunol.</i> , 151:2326-35, 1993.	
C43	Van Regenmortel, "Structural and Functional Approaches to the Study of Protein Antigenicity," <i>Immunology Today</i> , 10(8):266-272, 1989.	
C44	Written Opinion from PCT/IB04/01300 dated October 4, 2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--